MapLight Therapeutics, Inc. (MPLT): who owns it and who trades it
As of Nov 16, 2026, MPLT insiders reported 145 open-market sales worth $30.2M and 10 purchases worth $66.2M in the last 12 months, with 66% of the sale value made under pre-set 10b5-1 plans. The largest seller was Christopher A. Kroeger (CEO), with $13.1M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling MapLight Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns MPLT
107 funds and institutions reported MPLT shares worth $946M at the end of Q2 2026, about 62% of the company. The largest holder is Novo Holdings A/s with 8.7%.
Funds and institutions (13F) 62%Everyone else 38%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Novo Holdings A/s | 3.69M | 8.69% | $132M | No change |
| Fcpm III Services B.v. | 3.23M | 7.60% | $116M | No change |
| T. Rowe Price Investment Management, Inc. | 2.78M | 6.56% | $99.7M | -1% |
| Goldman Sachs Group Inc | 1.95M | 4.59% | $69.8M | -2% |
| T. Rowe Price Associates | 1.42M | 3.35% | $51M | +1162% |
| BlackRock, Inc. | 1.03M | 2.42% | $36.7M | -23% |
| Nan Fung Group Holdings Ltd | 971,253 | 2.29% | $34.8M | No change |
| 5AM Venture Management, LLC | 950,011 | 2.24% | $34M | No change |
| Sanofi | 912,041 | 2.15% | $32.7M | No change |
| State Street Corp | 852,150 | 2.01% | $30.5M | +151% |
| FMR LLC (Fidelity) | 823,556 | 1.94% | $29.5M | +303% |
| Vanguard Capital Management LLC | 784,150 | 1.85% | $28.1M | +9% |
| Blue Owl Capital Holdings LP | 729,929 | 1.72% | $26.2M | -27% |
| Paradigm Biocapital Advisors LP | 685,852 | 1.62% | $24.6M | New |
| Pivotal bioVenture Partners Investment Advisor LLC | 611,446 | 1.44% | $21.9M | No change |
| Velan Capital Investment Management LP | 492,893 | 1.16% | $17.7M | No change |
| Siren, L.L.C. | 450,000 | 1.06% | $16.1M | No change |
| Capital World Investors | 415,730 | 0.98% | $14.9M | New |
| Geode Capital Management, LLC | 402,051 | 0.95% | $14.4M | -16% |
| Baker Bros. Advisors LP | 364,705 | 0.86% | $13.1M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, MPLT insiders reported $66.2M of open-market purchases and $30.2M of sales. 66% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale | 15,355 | $8.08 | $124K | Form 4 |
| Oct 15, 2026 | Jonathan Gillis | CFO | Sale | 10,167 | $8.08 | $82.1K | Form 4 |
| Oct 15, 2026 | Kristopher Hanson | General Counsel | Sale | 9,020 | $8.08 | $72.9K | Form 4 |
| Oct 15, 2026 | Anatol Kreitzer | Chief Discovery Officer | Sale | 12,248 | $7.84 | $96K | Form 4 |
| Oct 15, 2026 | Christopher A. Kroeger | CEO | Sale | 73,691 | $8.08 | $595K | Form 4 |
| Oct 15, 2026 | James Woodruff Lillie | Chief Scientific Officer | Sale | 11,513 | $8.08 | $93K | Form 4 |
| Sep 16, 2026 | Kristopher Hanson | General Counsel | Sale plan | 16,509 | $11.67 | $193K | Form 4 |
| Aug 14, 2026 | Catalyst4, Inc. | 10% owner | Purchase | 4.40M | $11.38 | $50.1M | Form 4 |
| Aug 3, 2026 | James Woodruff Lillie | Chief Scientific Officer | Sale plan | 22,082 | $12.54 | $277K | Form 4 |
| Jul 30, 2026 | Catalyst4, Inc. | 10% owner | Purchase | 1.00M | $13.00 | $13M | Form 4 |
| Jul 29, 2026 | Catalyst4, Inc. | 10% owner | Purchase | 3,000 | $12.63 | $37.9K | Form 4 |
| Jul 28, 2026 | Catalyst4, Inc. | 10% owner | Purchase | 65,137 | $11.69 | $761K | Form 4 |
| Jul 28, 2026 | Catalyst4, Inc. | 10% owner | Purchase | 141,088 | $10.74 | $1.5M | Form 4 |
| Jul 28, 2026 | Troy Cox | Director | Purchase | 15,620 | $9.52 | $149K | Form 4 |
| Jul 17, 2026 | Jonathan Gillis | CFO | Sale plan | 16,969 | $37.61 | $638K | Form 4 |
| Jul 17, 2026 | Jonathan Gillis | CFO | Sale plan | 600 | $36.51 | $21.9K | Form 4 |
| Jul 17, 2026 | Jonathan Gillis | CFO | Sale plan | 900 | $38.17 | $34.4K | Form 4 |
| Jul 17, 2026 | Anatol Kreitzer | Chief Discovery Officer | Sale plan | 200 | $38.39 | $7.7K | Form 4 |
| Jul 17, 2026 | Anatol Kreitzer | Chief Discovery Officer | Sale plan | 14,140 | $37.70 | $533K | Form 4 |
| Jul 17, 2026 | Anatol Kreitzer | Chief Discovery Officer | Sale plan | 2,833 | $37.05 | $105K | Form 4 |
| Jul 17, 2026 | Christopher A. Kroeger | CEO | Sale | 16,779 | $37.90 | $636K | Form 4 |
| Jul 17, 2026 | James Woodruff Lillie | Chief Scientific Officer | Sale | 2,077 | $37.90 | $78.7K | Form 4 |
| Jul 17, 2026 | Kristopher Hanson | General Counsel | Sale | 1,130 | $37.90 | $42.8K | Form 4 |
| Jul 17, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale plan | 3,656 | $37.90 | $139K | Form 4 |
| Jul 16, 2026 | Jonathan Gillis | CFO | Sale plan | 6,979 | $36.66 | $256K | Form 4 |
| Jul 16, 2026 | Jonathan Gillis | CFO | Sale plan | 1,476 | $37.44 | $55.3K | Form 4 |
| Jul 16, 2026 | Anatol Kreitzer | Chief Discovery Officer | Sale plan | 1,592 | $37.44 | $59.6K | Form 4 |
| Jul 16, 2026 | Anatol Kreitzer | Chief Discovery Officer | Sale plan | 7,464 | $36.66 | $274K | Form 4 |
| Jul 16, 2026 | Christopher A. Kroeger | CEO | Sale | 28,091 | $37.26 | $1M | Form 4 |
| Jul 16, 2026 | Christopher A. Kroeger | CEO | Sale | 92 | $37.96 | $3.5K | Form 4 |
| Jul 16, 2026 | Christopher A. Kroeger | CEO | Sale | 40,899 | $36.46 | $1.5M | Form 4 |
| Jul 16, 2026 | James Woodruff Lillie | Chief Scientific Officer | Sale | 12 | $37.96 | $456 | Form 4 |
| Jul 16, 2026 | James Woodruff Lillie | Chief Scientific Officer | Sale | 3,526 | $37.26 | $131K | Form 4 |
| Jul 16, 2026 | James Woodruff Lillie | Chief Scientific Officer | Sale | 5,009 | $36.45 | $183K | Form 4 |
| Jul 16, 2026 | Kristopher Hanson | General Counsel | Sale | 3,331 | $37.26 | $124K | Form 4 |
| Jul 16, 2026 | Kristopher Hanson | General Counsel | Sale | 4,776 | $36.45 | $174K | Form 4 |
| Jul 16, 2026 | Kristopher Hanson | General Counsel | Sale | 11 | $37.96 | $418 | Form 4 |
| Jul 16, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale plan | 19 | $37.96 | $721 | Form 4 |
| Jul 16, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale plan | 5,865 | $37.26 | $219K | Form 4 |
| Jul 16, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale plan | 9,163 | $36.46 | $334K | Form 4 |
| Jul 15, 2026 | Jonathan Gillis | CFO | Sale plan | 5,356 | $36.13 | $194K | Form 4 |
| Jul 15, 2026 | Jonathan Gillis | CFO | Sale plan | 4,699 | $36.94 | $174K | Form 4 |
| Jul 15, 2026 | Anatol Kreitzer | Chief Discovery Officer | Sale plan | 4,510 | $36.94 | $167K | Form 4 |
| Jul 15, 2026 | Anatol Kreitzer | Chief Discovery Officer | Sale plan | 5,545 | $36.13 | $200K | Form 4 |
| Jul 15, 2026 | Christopher A. Kroeger | CEO | Sale | 18,950 | $36.00 | $682K | Form 4 |
| Jul 15, 2026 | Christopher A. Kroeger | CEO | Sale | 42,738 | $36.99 | $1.6M | Form 4 |
| Jul 15, 2026 | Christopher A. Kroeger | CEO | Sale | 90 | $37.54 | $3.4K | Form 4 |
| Jul 15, 2026 | James Woodruff Lillie | Chief Scientific Officer | Sale | 5,393 | $36.99 | $199K | Form 4 |
| Jul 15, 2026 | James Woodruff Lillie | Chief Scientific Officer | Sale | 12 | $37.54 | $450 | Form 4 |
| Jul 15, 2026 | James Woodruff Lillie | Chief Scientific Officer | Sale | 2,238 | $36.00 | $80.6K | Form 4 |
| Jul 15, 2026 | Kristopher Hanson | General Counsel | Sale | 5,103 | $36.99 | $189K | Form 4 |
| Jul 15, 2026 | Kristopher Hanson | General Counsel | Sale | 2,147 | $36.00 | $77.3K | Form 4 |
| Jul 15, 2026 | Kristopher Hanson | General Counsel | Sale | 10 | $37.54 | $375 | Form 4 |
| Jul 15, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale plan | 4,465 | $36.00 | $161K | Form 4 |
| Jul 15, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale plan | 8,972 | $36.99 | $332K | Form 4 |
| Jul 15, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale plan | 7,845 | $37.04 | $291K | Form 4 |
| Jul 15, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale plan | 7,155 | $36.16 | $259K | Form 4 |
| Jul 15, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale plan | 18 | $37.54 | $676 | Form 4 |
| May 18, 2026 | Christopher A. Kroeger | CEO | Sale plan | 198 | $28.15 | $5.6K | Form 4 |
| May 18, 2026 | Christopher A. Kroeger | CEO | Sale plan | 118,037 | $27.19 | $3.2M | Form 4 |
| May 11, 2026 | Kristopher Hanson | General Counsel | Sale plan | 5,808 | $30.56 | $177K | Form 4 |
| May 11, 2026 | Kristopher Hanson | General Counsel | Sale plan | 6,979 | $30.04 | $210K | Form 4 |
| May 11, 2026 | Kristopher Hanson | General Counsel | Sale plan | 846 | $28.70 | $24.3K | Form 4 |
| May 11, 2026 | Kristopher Hanson | General Counsel | Sale plan | 284 | $27.61 | $7.8K | Form 4 |
| May 11, 2026 | Christopher A. Kroeger | CEO | Sale plan | 877 | $28.70 | $25.2K | Form 4 |
| May 11, 2026 | Christopher A. Kroeger | CEO | Sale plan | 6,871 | $30.04 | $206K | Form 4 |
| May 11, 2026 | Christopher A. Kroeger | CEO | Sale plan | 5,890 | $30.56 | $180K | Form 4 |
| May 11, 2026 | Christopher A. Kroeger | CEO | Sale plan | 342 | $27.57 | $9.4K | Form 4 |
| May 8, 2026 | Christopher A. Kroeger | CEO | Sale plan | 1,582 | $28.56 | $45.2K | Form 4 |
| May 8, 2026 | Christopher A. Kroeger | CEO | Sale plan | 29,624 | $27.48 | $814K | Form 4 |
| May 8, 2026 | Christopher A. Kroeger | CEO | Sale plan | 3,205 | $29.20 | $93.6K | Form 4 |
| May 7, 2026 | Christopher A. Kroeger | CEO | Sale plan | 5,220 | $29.15 | $152K | Form 4 |
| May 7, 2026 | Christopher A. Kroeger | CEO | Sale plan | 14,880 | $28.47 | $424K | Form 4 |
| May 7, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale plan | 4,321 | $28.52 | $123K | Form 4 |
| May 7, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale plan | 117 | $29.10 | $3.4K | Form 4 |
| May 7, 2026 | James Woodruff Lillie | Chief Scientific Officer | Sale plan | 721 | $28.28 | $20.4K | Form 4 |
| May 6, 2026 | Vishwas Setia | CFO | Sale plan | 8,496 | $28.04 | $238K | Form 4 |
| May 6, 2026 | Vishwas Setia | CFO | Sale plan | 2,068 | $29.07 | $60.1K | Form 4 |
| May 6, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale plan | 8,152 | $28.04 | $229K | Form 4 |
| May 6, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale plan | 15,900 | $29.13 | $463K | Form 4 |
| May 6, 2026 | James Woodruff Lillie | Chief Scientific Officer | Sale plan | 16,421 | $29.13 | $478K | Form 4 |
| May 6, 2026 | James Woodruff Lillie | Chief Scientific Officer | Sale plan | 8,390 | $28.04 | $235K | Form 4 |
| May 6, 2026 | Christopher A. Kroeger | CEO | Sale plan | 15,603 | $29.13 | $455K | Form 4 |
| May 6, 2026 | Christopher A. Kroeger | CEO | Sale plan | 8,098 | $28.04 | $227K | Form 4 |
| May 5, 2026 | Vishwas Setia | CFO | Sale plan | 9,935 | $28.12 | $279K | Form 4 |
| May 5, 2026 | Vishwas Setia | CFO | Sale plan | 968 | $29.00 | $28.1K | Form 4 |
| May 5, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale plan | 9,645 | $28.12 | $271K | Form 4 |
| May 5, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale plan | 931 | $29.00 | $27K | Form 4 |
| May 5, 2026 | James Woodruff Lillie | Chief Scientific Officer | Sale plan | 963 | $29.00 | $27.9K | Form 4 |
| May 5, 2026 | James Woodruff Lillie | Chief Scientific Officer | Sale plan | 10,132 | $28.12 | $285K | Form 4 |
| May 5, 2026 | Christopher A. Kroeger | CEO | Sale plan | 9,544 | $28.12 | $268K | Form 4 |
| May 5, 2026 | Christopher A. Kroeger | CEO | Sale plan | 928 | $29.00 | $26.9K | Form 4 |
| May 4, 2026 | Vishwas Setia | CFO | Sale plan | 4,803 | $27.36 | $131K | Form 4 |
| May 4, 2026 | Vishwas Setia | CFO | Sale plan | 8,989 | $28.28 | $254K | Form 4 |
| May 4, 2026 | Vishwas Setia | CFO | Sale plan | 325 | $29.56 | $9.6K | Form 4 |
| May 4, 2026 | Vishwas Setia | CFO | Sale plan | 787 | $30.12 | $23.7K | Form 4 |
| May 4, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale plan | 9,180 | $27.50 | $252K | Form 4 |
| May 4, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale plan | 5,460 | $28.37 | $155K | Form 4 |
| May 4, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale plan | 312 | $29.56 | $9.2K | Form 4 |
| May 4, 2026 | Erin Pennock Foff | Chief Medical Officer | Sale plan | 700 | $30.08 | $21.1K | Form 4 |
Latest 100 of 155 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Catalyst4, Inc. | 10% owner | $65.4M | – | Aug 14, 2026 |
| Christopher A. Kroeger | Chief Executive Officer, Director | – | $13.1M | Oct 15, 2026 |
| Jonathan Gillis | CAAO and PAO | – | $3.6M | Oct 15, 2026 |
| Erin Pennock Foff | Chief Medical Officer | – | $3.5M | Oct 15, 2026 |
| Anatol Kreitzer | Chief Discovery Officer | – | $2.9M | Oct 15, 2026 |
| James Woodruff Lillie | Chief Scientific Officer | – | $2.7M | Oct 15, 2026 |
| Kristopher Hanson | General Counsel | – | $1.7M | Oct 15, 2026 |
| Robert C. Malenka | Director | – | $1.6M | Apr 15, 2026 |
| Vishwas Setia | Chief Financial Officer | – | $1.1M | May 6, 2026 |
| George Pavlov | Director | $441K | – | Feb 20, 2026 |
| Timothy John Garnett | Director | $253K | – | Feb 10, 2026 |
| Troy Cox | Director | $149K | – | Jul 28, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
MPLT short interest
3.25M MPLT shares are sold short. Over the last 12 reports the number of shares short went up 139%.
As of Oct 30, 2026, 3.25M MPLT shares were sold short, down 2.1% from the report before. At the average daily volume of 315,511 shares, buying them all back would take about 10.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.25M | – | -2% | 315,511 | 10.3 |
| Oct 15, 2026 | 3.32M | – | +6% | 399,424 | 8.3 |
| Sep 30, 2026 | 3.15M | 7.42% | -5% | 542,975 | 5.8 |
| Sep 15, 2026 | 3.30M | 7.77% | -4% | 542,849 | 6.1 |
| Aug 31, 2026 | 3.43M | 8.07% | +6% | 601,142 | 5.7 |
| Aug 14, 2026 | 3.24M | 7.63% | -10% | 589,830 | 5.5 |
| Jul 31, 2026 | 3.58M | 8.44% | -0% | 2.17M | 1.6 |
| Jul 15, 2026 | 3.59M | 8.45% | +39% | 533,984 | 6.7 |
| Jun 30, 2026 | 2.58M | 6.07% | +36% | 637,655 | 4.0 |
| Jun 15, 2026 | 1.90M | 4.48% | +22% | 291,955 | 6.5 |
| May 29, 2026 | 1.56M | 3.68% | +15% | 291,390 | 5.4 |
| May 15, 2026 | 1.36M | 3.21% | -22% | 243,280 | 5.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
MapLight Therapeutics company events
MapLight Therapeutics filed 10 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Aug 13, 2026.
- Aug 13, 2026AgreementMapLight Therapeutics, Inc. entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement transaction (i) 9,197,887 shares of the Company’s voting common stock, par value $0.0001 per… Filing
- Jul 27, 2026AnnouncementThe Company issued a press release announcing the ZEPHYR Trial Results. Filing
- Jun 24, 2026VoteReported shareholder vote results. Filing
- Jun 22, 2026AnnouncementThe Company issued a press release announcing the IRIS Trial Results. Filing
- Jun 18, 2026LeadershipVishwas Setia was separated as the Chief Financial Officer of MapLight Therapeutics, Inc., effective immediately, following a review of a human resources violation. Filing
- May 14, 2026ResultsReleased financial results. Filing
- Apr 29, 2026LeadershipRobert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of Directors of MapLight Therapeutics, Inc. of their respective decisions not to stand for reelection at the Company’s Annual Meeting of Stockholders to be held on June 23, 2026. Filing
- Mar 26, 2026ResultsReleased financial results. Filing
- Jan 9, 2026ResultsReleased financial results. Filing
- Dec 4, 2025ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
MapLight Therapeutics financials
Famous investors that hold MPLT
3 of the 50 well-known investors we track reported holding MPLT in their latest 13F filing. The largest position is Steve Cohen's, worth $4.3M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 426,261 | $4.3M | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 423,678 | $4.3M | 0.0% | +229% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 85,475 | $871K | 0.0% | +232% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named MPLT in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 13G/A | 8.4% |
| Nov 16, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 13G/A | 8.4% |
| Nov 16, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 1.7% |
| Nov 16, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 1.7% |
Questions about MapLight Therapeutics, Inc. (MPLT) stock
Who owns the most MPLT stock?
The largest reported owner of MapLight Therapeutics, Inc. (MPLT) is Novo Holdings A/s, with 8.7% of the company. In total, 107 funds and institutions reported holding MPLT at the end of Q2 2026, together about 62% of the shares. See the largest owners.
Are MPLT insiders buying or selling?
In the last 12 months, MPLT insiders reported 10 open-market purchases worth $66.2M and 145 sales worth $30.2M. The latest trade was on Oct 15, 2026. See every trade.
What is the short interest in MPLT?
As of Oct 30, 2026, 3.25M MPLT shares were sold short, down 2.1% from the report before. At the average daily volume of 315,511 shares, buying them all back would take about 10.3 trading days (days to cover). See the history.
Which famous investors hold MPLT?
3 of the 50 well-known investors we track reported MPLT in their latest 13F filing, including Steve Cohen, Israel Englander, Ken Griffin. The largest position is worth $4.3M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.